Citadel Advisors’s AtriCure ATRC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-7,400
| Closed | -$261K | – | 12628 |
|
|
2025
Q3 | $261K | Sell |
7,400
-2,900
| -28% | -$99.9K | ﹤0.01% | 10670 |
|
|
2025
Q2 | $338K | Buy |
10,300
+3,400
| +49% | +$110K | ﹤0.01% | 9536 |
|
|
2025
Q1 | $223K | Sell |
6,900
-5,400
| -44% | -$200K | ﹤0.01% | 10242 |
|
|
2024
Q4 | $376K | Buy |
12,300
+300
| +3% | +$9.65K | ﹤0.01% | 9190 |
|
|
2024
Q3 | $336K | Sell |
12,000
-600
| -5% | -$14.8K | ﹤0.01% | 9082 |
|
|
2024
Q2 | $287K | Buy |
12,600
+2,800
| +29% | +$64.6K | ﹤0.01% | 9238 |
|
|
2024
Q1 | $298K | Sell |
9,800
-1,500
| -13% | -$50.2K | ﹤0.01% | 9461 |
|
|
2023
Q4 | $403K | Buy |
11,300
+11,100
| +5,550% | +$413K | ﹤0.01% | 8551 |
|
|
2023
Q3 | $8.76K | Sell |
200
-1,300
| -87% | -$63.4K | ﹤0.01% | 13161 |
|
|
2023
Q2 | $74K | Buy |
1,500
+600
| +67% | +$27.7K | ﹤0.01% | 11327 |
|
|
2023
Q1 | $37.3K | Buy |
900
+400
| +80% | +$16.6K | ﹤0.01% | 12507 |
|
|
2022
Q4 | $22.2K | Sell |
500
-7,000
| -93% | -$292K | ﹤0.01% | 13062 |
|
|
2022
Q3 | $293K | Buy |
7,500
+2,300
| +44% | +$105K | ﹤0.01% | 9630 |
|
|
2022
Q2 | $212K | Buy |
5,200
+1,700
| +49% | +$80.5K | ﹤0.01% | 10578 |
|
|
2022
Q1 | $230K | Buy |
+3,500
| New | +$227K | ﹤0.01% | 11188 |
|
|
2021
Q4 | – | Sell |
-7,200
| Closed | -$501K | – | 13762 |
|
|
2021
Q3 | $501K | Sell |
7,200
-1,100
| -13% | -$84.6K | ﹤0.01% | 9856 |
|
|
2021
Q2 | $658K | Sell |
8,300
-2,300
| -22% | -$167K | ﹤0.01% | 9389 |
|
|
2021
Q1 | $695K | Buy |
+10,600
| New | +$653K | ﹤0.01% | 8958 |
|
|
2020
Q3 | – | Sell |
-7,100
| Closed | -$319K | – | 10046 |
|
|
2020
Q2 | $319K | Buy |
+7,100
| New | +$309K | ﹤0.01% | 7818 |
|
|
2019
Q4 | – | Sell |
-8,700
| Closed | -$217K | – | 9082 |
|
|
2019
Q3 | $217K | Sell |
8,700
-176,600
| -95% | -$5.04M | ﹤0.01% | 8048 |
|
|
2019
Q2 | $5.53M | Buy |
185,300
+172,200
| +1,315% | +$5.03M | ﹤0.01% | 2957 |
|
|
2019
Q1 | $351K | Buy |
+13,100
| New | +$398K | ﹤0.01% | 7379 |
|
|
2018
Q4 | – | Sell |
-6,800
| Closed | -$238K | – | 9077 |
|
|
2018
Q3 | $238K | Sell |
6,800
-2,200
| -24% | -$69.7K | ﹤0.01% | 7963 |
|
|
2018
Q2 | $243K | Buy |
+9,000
| New | +$212K | ﹤0.01% | 7565 |
|
|
2016
Q4 | – | Sell |
-10,000
| Closed | -$158K | – | 7229 |
|
|
2016
Q3 | $158K | Sell |
10,000
-2,500
| -20% | -$38.4K | ﹤0.01% | 6435 |
|
|
2016
Q2 | $177K | Buy |
+12,500
| New | +$191K | ﹤0.01% | 5914 |
|
|
2015
Q4 | – | Sell |
-5,500
| Closed | -$121K | – | 8705 |
|
|
2015
Q3 | $121K | Buy |
+5,500
| New | +$137K | ﹤0.01% | 6770 |
|
Other funds holding ATRC
HRCM
NAMI
Citadel Advisors's ATRC Position: Q2 2026 in Review
Citadel Advisors increased its AtriCure (ATRC) stake by 103% in Q2 2026, buying an estimated $2.53M and bringing the position to 177,339 shares worth $4.96M. The position accounts for ﹤0.01% of the portfolio, ranked #4733.
Citadel Advisors first reported a position in ATRC in Q4 2013 and has held it in 41 quarters since. The position peaked at $65.8M in Q2 2021. 252 funds tracked by Wall St. Rank hold ATRC as of Q2 2026.
- Citadel Advisors held 177,339 shares of AtriCure worth $4.96M as of Q2 2026.
- Citadel Advisors bought 89,992 AtriCure shares in Q2 2026, an estimated $2.53M.
- AtriCure made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4733 holding.
- Citadel Advisors first reported a position in AtriCure in Q4 2013 and has held it in 41 quarters since.
- Citadel Advisors's AtriCure position peaked at $65.8M in Q2 2021.
- 252 funds tracked by Wall St. Rank held AtriCure as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.